NZ212301A

NZ212301A - Pharmaceutical compositions containing peroxydiphosphoric acid derivatives

Info

Publication number: NZ212301A
Application number: NZ212301A
Authority: NZ
Inventors: A Gaffar
Original assignee: Colgate Palmolive Co
Priority date: 1984-06-27
Filing date: 1985-06-04
Publication date: 1988-04-29
Also published as: PT80707B; FI852504L; DK168191B1; WO1986000225A1; FR2566665A1; SE468501B; ES544565A0; ES8801122A1; JPS6140217A; FR2566665B1; MA20467A1; SE8502876D0; CH668361A5; FI84697C; IE58434B1; KR860000070A; IT8548226A0; DK248085A; FI852504A0; DE3523263A1

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number £12301 21230 Prfr ' r <? y art ... . W'^3 •••••«»• • «•««•« ••*••••• Cc. Specification Filed: c\r-z::: .a&jt&fifek Publication Date: ?.?. P.O. J cm ma I, No: ... NO DRAW^uS Patents Form No. 5 Number PATENTS ACT 1953 Dated COMPLETE SPECIFICATION INHIBITION OF TUMOR DEVELOPMENT #We COLGATE-PALMOLIVE COMPANY of 300 Park Avenue, New York, New York 10022, United States of America, a corporation organised under the laws of the State of Delaware, United States of America do hereby declare the invention for which fywe pray that a Patent may be granted to foe/us, and the method by which it is to be performed, to be particularly described in and by the following statement: - I - 212301 This invention relates to the inhibition of tumor development with respect to tumor cells iji vitro and actual tumor development iji vivo in warm blooded non-human animals. The disease of cancer results from development of malignant tumors. A vast amount of medical research has been committed to reducing and overcoming the scourge of cancer. To date, a cure for cancer has not been found. However, much has been learned of the mechanism by which warm blooded ;non-human animals avoid afflication with cancer. The present invention builds on this knowledge to provide a material which inhibits tumor development and a method for inhibiting such development. BACKGROUND Among the cells contained in mammalian bodv fluids are lymphocytes,monocvtes, macrophages and polymorphonuclar cells. These cells act as a natural surveillance ' system against tumor development in lower mammals, such j i as rodents. In recent years, it has been observed that a particular subpopulation of lymphocytes or lymphoid cells, termed "Natural Killer" or "NK" cells, destroy tumor cells and thus prevent development of cancer. The weight of evidence suggests i that NK cells possess cytolytic activity related to i generation of an active oxygen species such as y\ fc N -2- 1 FEB 1988 v 212301 hydrogen peroxide (H2O2) or oxygen-containing radicals, e.g. hydroxyl anion (*OH) and superoxide anion (Oj"). The NK cells and active oxygen phemonena are described by Herberman et al, Science, Vol. 214, 2 October 1981, pages 24-30, Roder et al. Nature; Vol. 298, 5 August 1982, pages 569-572; Nathan et al, Journal of Immunology, Vol. 129, No. 5, November, 1982, pages 2164-2171; and Mavier et al , Journal of Immunology, Vol. 132, No. 4, April, 1984, pages 1980-1986. Of course, there are many compounds which release active oxygen species. However, that factor alone has not meant that such compound could be introduced into a body to supplement the function of NK cells or where tumor formation is not sufficiently occuring to provide the function of NK cells and inhibit tumor development. Compounds which release active oxygen species generally do so quickly, while effectiveness against tumor development in warm blooded non-human animals would appear to require at least a slower and more sustained release rate. Until this invention, this had not been effectively achieved. When oxygen release is too fast both tumorous and normal cells may be attacked. -3- eA , H FEB 1988^ 212301 In U.S. Patent No . 4 ,041,149 , granted August 9, 1977, to myself and co-inventors, a comnosition vas described in various f o rms , inc 1 ud inp, as a dental tablet, which inhibited formation of mouth odor in which the active ingredient was a peroxydiphosphate. Peroxydiphosphate compound differs from most oxygen providing compounds in that it does not provide an initial burst of hvdrogen peroxide. Rather, it releases hydrogen peroxide slowly such that when equivalent concentrations are compared to hydrogen peroxide, the amount of oxygen released by the peroxydiphosphate is one-tenth the amount of available oxygen released by hvdrogen peroxide. Moreover, only about 50% of the active oxygen is released in 20 hours at 25°C in the presence of alkaline phosphatase or acid phosphatase each of ! i which is present in the bodies of warm blooded non-human animalsj including mice, rats, e t c . _ - ADVANTAGES It is an advantage of this invention that tumor development is inhibited on tumor cells in vitro and in actual malignant tumor development ill vivo in warm blooded non-human animals, such as rodents. It is a further advantage of this invention that methods are provided for inhibiting tumor formation by introducing a slow oxygen releasing material into a living host. 2 1 ? ^ f SUMMARY In accordance vith certain of its aspects, this invention relates to a composition comprising a dosage amount of about 0.1-10% of a non-toxic water-soluble pharnBceutL-cally acceptable cocipound derivative of peroxydiphosphoric acid dissolved or dispersed in a pharmaceutical carrier. In accordance with certain of its further aspects, this invention relates to a method of inhibiting tumor formation having malignant tumor cells in which a composition comprising a non-toxic dosage amount of about 0.1-6 gm per kg body weight of a warm blooded animal of a non-toxic water-soluble pharmaceutically acceptable compound derivative of peroxydiphosphoric acid dissolved or dispersed within a pharmaceutical carrier is administered to a warm blooded animal host by oral ingestion in a regimen which provides about j 0.1-6 gm per kg body weight of said warm blooded j animal per day. I i In accordance with certain of its further aspects this invention relates to a method of Inhibiting tumor formation in which a composition comprising a non-toxic dosage amount of about 0.1-2 gm per kg body weight of a warm blooded animal having malignant tumor cells of a non-toxic water-soluble pharmaceutically acceptable compound derivative of peroxydiphosphoric acid dissolved or dispersed in a pharmaceutical carrier is administered systemically to a warm blooded animal host in a regimen which provides about 0.1-2 gm per kg body weight of said warm blooded animal. -5- 212301 DETAIL The peroxydiphosphate compound (PDP) is in the form of a non-toxic pharmaceutically acceptable compound, which goes beyond salt indicated in earlier mentioned U.S. Patent 4,041,149. Compounds include alkali metal (e.g. lithium, sodium and potassium) alkaline earth metal (e.g. magnesium, calcium and strontium), zinc and tin salts as well as organic peroxydiphosphate C^_^2 alkyl, adenyl , guanyl, cytosyl and thymyl" esters and also quaternary ammonium and the like salts. Alkali metal, particularly potassium salt is preferred from among the inorganic cations. The tetrapotassium peroxydiphosphate is a stable, odorless, finely divided, free-flowing, white non-hygroscopic crystalline solid having a molecular weight of 346.35 and an active oxygen content of 4.6%. Tetrapotassium peroxydiphosphate is 47-51% water-soluble at 0°-61°C, but insoluble in common solvents such as acetonitrile, alcohols, ethers, ketones, dimethyl formamide , dimethyl sulfoxide, and the like. A 2% aqueous solution has a pH of about 9.6 and a saturated solution thereof a pH of about 10,9. A 10% solution in water at 25°C showed no active oxygen loss after four months; and at 50°C a 10JS solution showed an active oxygen loss of 3% in 6 months. -6- 212301 The organic salts can be particularly suitable for administration against malignant tumors. From among the organic esteis those providing hydrophobic properties such as C alkvl radical and those which facilitate 1-12 the rapid uptake of peroxydiphosphate moiety by the cells, such as adenvl , guanvl, cvtosyl' and thymyl, . esters are preferred. Pharmaceutical carriers suitable for oral ingestion are coated tablets composed of material which resists breakdown by gastric acids in the stomach pH (about 1-3) since peroxydiphosphate would be inactivated by such gastric acids. Rather, the carriers, with t abl e t ed .1 gr anul es of the peroxydiphosphoric acid salt solid material therein, are dissolved by intestinal fluids which have a higher pH (about 5.5-10) and do not inactivate the peroxydiphosphate, leaving it ] subject to enzymatic action by phosphatase present j | in humans or other warm blooded animals. A desirable tablet ccrt-j ing solution is composed of a fatty acid ester such as N-butyl stearate (typically about 40-50, preferably about 45 parts by weight), wax such as carnuba wax (typically about 15-25, preferably about 20 parts by weight), fatty acid such as stearic acid (typically about 20-30 parts, preferably 25 parts by weight) and cellulose ester, such as cellulose acetate phthalate (typically about 5-15, preferably about 10 parts by weight) and organic solvent (typically about 400-900 parts). Other desirable -7- ...... Vn rI ^ ! :jrj ! Kll FEB W88 | coating materials include Bhellac and copolymers of maleic anhydride and ethylenic compounds such as polyvinyl methyl ether. Such coatings are distinct from tablets which are broken down in the oral cavity in which the tablet material typically contains about 80-90 parts by weight of mannitol and about 30-40 parts by weight of magnesium stearate. Tabletted granules of the peroxydiphosphate salt are formed by blending about 30-50 parts by weight of the peroxydiphosphate salt with about 45-65 parts by weight of a polyhvdroxy sugar solid such as mannitol and wetting with about 20-35 parts by weight of a polyhvdroxy sugar compound solution such as sorbitol, screening to size, blending with about 20-35 parts by weight of a binding agent such as magnesium stearate and compressing the granules into tablets with a tablet compressing machine. The tabletted granules are coated by spraying a foam of a solution of the coating material thereon and drying to remove solvent. Such tablets differ from dental tablets which are typically compressed granules without a special protective coating. An effective dosage of administration of peroxydiphosphate with a prescribed regimen, when administration is by oral ingestion, is about 0.1-6 gm per kg of body weight daily; when administration is systemic, such as by intramuscular, intraperitoneal or intravenous injection, the dosage is about 0.1-2 gm per kg of body weight daily. . T 8- '-.J <r^s a \ f Physiologically acceptable nyrogerv-free solvents are suitable carriers for use in the art-recognized manner for systemic administration. Saline solution buffered with phosphate to a physiological pH of about 7 to 7.A is the preferred carrier for systemic administration. Such solvents are distinct from water-humectant vehicles typically used in dentifrices. Such solution is typically prepared by sterilizing deionized distilled water, checking to insure non-pyrogenicity using the Limulus amebocyte lysate (LAL) test described by Tsuji et al in "Pharmaceutical Manufacturing", October, 1984, pages 35-41, and then adding thereto a phosphate buffer (pH e.g. about 8.5-10) made in pyrogen free sterile water and about 1-100 nigs, peroxydiphosphate compound derivative and sodium chloride to a concentration of about 0.5-1.5% bv weight. The solution can be packed in vials for use after being resterilized by passing through a micropore filter. As alternatives, other solutions such as Ringer's solution containing 0.86% by weight sodium chloride, 0.03% by weight potassium chloride and 0.033% bv weight calcium chloride may be used. -9- 2 1230 1 n /T\ Peroxydiphosphate compound (PDP) release hvdrogen peroxide slowly in the presence of phosphatase enzymes in accordance with the following equation: 0 -3 || |( phosphatases || H,0 H 0o+P0, ^. n n r\ n r\ n n " n ' V 2 ^ 0 0 II II phosphatases || H,0 H 0,+P0, Xy-O-P-O-O-P-O — -■ ■> -0-0-P-0- - \ 21 1 I I * 0 0 0— wherein X is a non-toxic pharmaceutically acceptable cation or anpletes i an organic ester moiety. Phosphatase to break down the peroxydiphosphate i I is present in saliva as well as in plasma, intestinal \ i fluids and white blood cells. The slow oxygen j release is particularly effective in supplementing the effectiveness of NK cells against malignant tumor cells which respond to peroxydiphosphate therapy. When warm blooded animals are treated with PDP in accordance with the present invention it is desirable to urovide a regimen whereby treatment continues at least until tumors are regressed. The following comparative examples Illustrate the invention. All amounts are by weight unless otherwise indicated. -10- 2 1 230 1 EXAMPLES Example 1; In Vitro Study of PDP Tumor Cytotoxicity In this study the effects of PDP are examined at different concentrations on the grovth of murine myeloma (SP2 line) cells (Table 1). Human gingival fibroblasts are used as normal cells control (Table 2). The cells are grown in Dulbecco's modified Eagles's medium supplemented with 102 fetal bovine serum, IX MEM vitamins, IXL-glutamine, IX NEAA3, IX gentamycin. They are incubated at 37°C in a humidified CO2 atmosphere. Approximately 1 to 3 x 10^ cells are put into each well of a 24 well microtiter plate containing 2 ml of the medium. PDP (potassium salt) in varying concentrations, is added. -11- * . : y;;Ql After incubation, the cell viability is determined by removing aliquots from the veils over the time specified in Table 1. The viability Is assessed by the trypan blue exclusion test. Fresh medium is added in each well, each day to maintain the necessary growth conditions. The inhibition was calculated by comparing Z of cells alive in phosphate buffer saline (PBS) vs. PDP. The data is summarized in Table 1. TABLE 1 EFFECTS OF PDP ON MURINE MYELOMA (SP? LINE) CELLS TREATMENT N NUMBER OF CELLS x 1Q5 X VIABLE CELLS (AT 72 HOURS) Control (PBS) 4 8.98 + 0.14 1002 , PDP pH 7.0 100 mcg/ml 4 1.86 + 0.14 47 500 mcg/ml 4 1.33 + 0.03 33 :J 1000 mcg/ml 4 1.07 + 0-17 29 l! 2500 mcg/ml 4 0.48 + 0.15 12 | These results show that compared to the buffer control, I * jj potassium salt of PDP is highly cytotoxic and inhibltatlve i ! to the murine myeloma (cancer) cells. I Table 2 describes the effects on normal cells (human I » gingival fibroblast). TABLE 2 EFFECTS ON PDP ON HUMAN GINGIVAL FIBROBLAST TREATMENT H NUMBER OF VIABLE CELLS X 105 ' 1 VIABLE " (AT 72 HOURS) CELLS Control (PBS) 4 2.67 + 0.17 100 PDP pH 7.0 100 mcg/ml 4 2.61 + 0.16 98 500 mcg/ml 4 2.58 + 0.13 97 1000 mcg/ml 4 2.12 + 0.15 79 2500 mcg/ml 4 1.97 + 0.11 74 -12- ' ~—'—1 27 JUNS985 212301 The data in Table 2 suggest no significant effect on cell growth at 100-500 mcg/ml of PDP but / that even on normal cells, viability is reduced at 1000 and 2500 mcg/ml. It is noteworthy that the effect on the myeloma tumor cells (Table 1) even at high concentrations is more pronounced than the effect with the normal cells (Table 2). Similar results are obtained with lithium, sodium, magnesium, calcium,strontium, zinc and stannous salts of PDP, organic peroxydiphosphate as well as C^_i2 alkyl, adenyl, guanyl, cytosyl, thymyl esters and tp. tramethvls ammonium salt of PDP. EXAMPLE 2: The Effects of PDP, Potassium Pyrophosphate (KPP) and PBS (Phosphate Buffered Saline) on Tumor Development in Vivo Seventy five genetically identical Balb/C mice having an average weight of 20 grams + 3 grams groups of 25 animals each: (a) control treated with phosphate buffer saline (PBS); (b) treated with potassium peroxydiphosphate (PDP) and PBS, pH 7.0; and (c) potassium pyrophosphate (KPP) and PBS as a phosphate control. Each animal receives 0.2 ml of Pristane intra- peritoneally (l.P.) to prime animals for malignant SP2 cells (murine myeloma carcinoma tumor cells) implantation. After three weeks, the animals are put on oral ingestion treatment regime as follows: Group (a) receiving via I.P. 0.2 ml of PBS; group (b) receiving 2.0 mg PDP suspended in 0.2 ml. of PBS, and group (c) -13- | * f FEB 1983 / ip, \ ^ eV c*5/; a' ': receiving 2.0 mg, of KPP in 0.2 ml of PBS, for three consecutive days. Forty-eight hours after the third injection, each animal is inoculated (I.P.) with 2 to 3 x 10^ cells of SP^ (mice tumor cells, aurine myeloma). Thereafter, the animals are given their respective materials, once daily for 5 days/week. That is, (a) PBS, (b) PDP or (c) KPP. The animals are scored for tumor development and death each week. The data is analyzed using the Mantel-Haenszel procedure (Statistical Aspects of the Analysis of Data from Retrospective Studies of Disease, J. National Cancer Institute, Vol. 3, 719-748, 1959). The data in Tables 3, A and 5 indicate that PDP is significantly effective in controlling tumor development in mice when compared to PBS or KPP,thereby evidencing that the effects in inhibiting tumor development is due to the provision of active oxygen species and not phosphate. -14- 2 1230 t TABLE 3 PBS* VS. KPP** TEN WEEK TUMOR DEVELOPEMENT STUDY WEEK TREATMENT TUMOR AND DEATH NO TUMOR AT RISK 1 -A PBS 11 1A 25 KPP 10 15 25 5 PBS A 10 1A KPP A 11 15 6 PBS 5 5 10 KPP 2 9 11 7 PBS 2 3 5 KPP A 5 9 8 PBS 0 3 3 KPP 1 A 5 9 PBS 2 1 3 KPP 3 1 A 10 PBS 1 0 1 KPP 0 1 1 Mantel -Haenszel chi-square » 0. 36 with 1, d.f. , p - 0.5: Odds ratio ■ 1. 3A These results are not significant and evidence no significant difference between PBS and KPP in reducing tumo r development in the animals. *PBS - Phosphate buffer saline **KPP ■ Potassium pyrophosphate. j -15- . i i t i[ • I 2 1 230 1 WEEK 1-4 10 TABLE 4 TEN WEEK TUMOR STUDY PBS* VS. PDP** TREATMENT TUMOR AND DEATH NO TUMOR AT RISK PBS 11 14 25 PDP 2 23 25 PBS 4 10 14 PDP 4 19 23 PBS 5 5 10 PDP 5 14 19 PBS 2 2 5 PDP 2 13 14 PBS 0 3 3 PDP 2 10 12 PBS 2 1 3 PDP 3 7 10 PBS 1 0 1 PDP 1 6 7 Mantel-Haenszel chi square = 10.40 with 1, d.f., P * 0.001 Odds ratio * 3.66. These data indicate that the PBS control group develop tumors significantly sooner than PDP treated animals (P - 0.001). *PBS " Phosphate buffer saline **PDP ■ Potassium peroxydiphosphate. 3 -16- i TABLE 5 TEN WEEK TUMOR STUDY KPP* VS. PDP*** WEEK TREATMENT TUMOR AND DEATH NO TUMOR AT RISK 1-4 KPP 10 15 25 PDP 2 23 25 5 KPP 4 11 15 PDP 4 19 23 6 KPP 2 9 11 PDP 5 14 19 7 KPP 4 5 9 PDP 2 14 14 8 KPP 1 4 5 PDP 2 10 12 9 KPP 3 1 4 PDP 3 7 10 10 KPP 0 1 1 PDP 1 6 7 Mantel-Haenszel chi square = 5.86 with 1, d.f., ** i o • o Odds ratio = 2.60. The data indicated that the KPP group develops tumors significantly sooner than PDP treated animals (P • 0.001). *KPP ■ Potassium pyrophosphate ***PDP * Potassium peroxydiphosphate Similar results can be observed when each of PBS, KPP and PDP are administered intramuscularly and intravenously in the same concentrations in PBS or orally in a concentration of 1 mg/ml (0.12) in a stable carrier of 45 parts of N-butyl stearate, 20 parts of carnauba wax, 25 parts of stearic acid and 10 parts of cellulose acetate phthalate. 212301 Similar results are obtained with other inorganic salts of PDP, particularly lithium, sodium, magnesiuni, calcium, strontium, zinc and stannous salts. Organic compounds of PDP, particularly Ci_i2 alkyl, adenyl , guanyj ,. cytosyl, thymyl esters and tetramethvl ammonium salts are also effective in countering growth of murine myeloma malignant tumor cells. EXAMPLE 3 500 parts of potassium peroxydiphosphate and 641 parts of mannitol are blended and wet with 32.5 parts of a 10% solution of sorbitol to form a wet granulate, o which is dried at 49 C and screened through a 12 mesh,l].S. sieve (1.68 mm screen openings). 35 parts of magnesium stearate is Chen added as a binder and tabletted granules are formed by compressing the composition on a tablet compressing ma chine. The tablets are coated with an enteric coating solution of the following composition: Cellulose acetate phthalate 120 parts Carnauba wax 30 parts Stearic acid 10 parts 95% ethanol 450 parts Acetone Q.S. to 1000 parts The coating is carried out by a pouring procedure in a conventional coating pan. -18- </div>

Claims

<div class="application article clearfix printTableText" id="claims"> 212301 When the tablets thus formed are Ingested, they pass through the stomach without breakdown and the coating is then dissolved by intestinal fluids. EXAMPLE 4 Deionized distilled water is stabilized at atmospheric pressure for 20 minutes in an autoclave. After cooling, it is tested for non-pyrogenicity using the Limulus Amebocvte Lysate (LAL) as described by Tsuji et al in "Pharmaceutical Manufacturing", October, 1984, pages 35-41. 50 parts of potassium peroxydiphosphate, sodium chloride in amount corresponding to 0.9% of solution and 0.1 M phosphate buffer containing KH^PO^ and NajHPO^, pH 9.4 are added to the pyrogen-free sterile water. The solution is then sterilized by passing it through a 0.5 micropore filter and is then packed in sterile files. Although the invention has been described with reference to specific examples, it will be apparent to one skilled in the art that various modifications can be made thereto which fall within its scope. -19- D 212301 WHAT WE CLAIM IS :

1. A composition comprising a dosage amount of 0.1—10 weight % of a non-toxic water-soluble pharmaceutically acceptable compound derivative of peroxydiphosphoric acid dissolved or dispersed in a pharmaceutical carrier which pharmaceutical carrier is a buffered phosphate saline solution having a pH of 7.0-7.4- or a coated tablet material which resists breakdown by gastric acids while being broken down by intestinal fluid at a pH of 5.5-10.

2. The composition claimed in Claim 1 wherein said pharmaceutical carrier is said buffered phosphate saline solution.

3. The composition claimed in Claim 1 wherein said pharmaceutical carrier is said coated tablet material which resists breakdown by gastric acids while being broken down by intestinal fluid at a pH of 5.5 to 10.

4. The composition claimed in Claim 3 wherein the coating of said tablet pharmaceutical carrier comprises 40-50 parts by weight of a fatty acid ester, 15-25 parts by weight of a wax, 20-30 parts by weight of a fatty acid and 5-15 parts by weight of a cellulose es ter.

5. The composition claimed in Claim 4 wherein said fatty acid ester is N-butyl stearate, said wax is carnauba wax, said fatty acid is stearic acid and said cellulose ester is cellulose acetate phthalate. -20- 1 CCD 1009 " i

6. The composition claimed in Claim 1 wherein said non-toxic water-soluble pharmaceutically acceptable compound derivative of peroxydiphosphoric acid is a salt selected from the group consisting of alkali metal, alkaline earth metal, zinc and tin salts.

7. The composition claimed in Claim 1 wherein said non-toxic water-soluble pharmaceutically acceptable compound derivative of peroxydiphosphoric acid is selected from the group consisting of Cj_12 alkyl, adenyl, guanyl, cytosyl, thymy L esters, and quaternary ammonium salts thereof.

8. The composition claimed in Claim 6 wherein said salt is potassium peroxydiphosphate.

9. The composition claimed in Claim 7 wherein said compound derivative is a C1-12 alkyl ester of peroxyd iphnsphor i j: I acid.

10. The composition claimed in Claim 7 wherein said compound derivative is adenyl, guanyl, cytosyl or thymyl ester of peroxydiphosphoric acid.

11. A method of inhibiting formation of malignant tumor cells in a warm blooded non-human animal in which a composition comprising 0. 1-6 gm per kg body weight of a warm blooded non-human animal of a non-toxic water-soluble pharmaceutically acceptable compound derivative of peroxydiphosphoric acid dissolved or dispersed within a pharmaceutical carrier which is a coated tablet which resists breakdown by gastric acids while being broken down by intestinal fluid at a pH of 5.5' to 10 is administered to a warm blooded nun-human animal by oral ingestion in a regimen which provides 0.1-6 gm per kg body weight of said warm blooded non-human animal per day.

12. The method claimed in Claim It wherein the coating of said tablet comprises 40-50 parts by weight of N-butyl stearate, 15-25 parts by weight of carnauba wax, 20-30 parts by weight of stearic acid and 5-15 parts by weight of cellulose acetate phthalate.

13. The method claimed in Claim 11 wherein said non-toxic, water-soluble pharmaceutically acceptable compound derivative of peroxydiphosphoric acid is a salt selected from the group consisting of alkali metal, alkaline earth metal, zinc and tin salts.

14. The method claimed in Claim 11 wherein said non-toxic water-soluble pharmaceutically acceptable compound derivative of peroxydiphosphoric acid is selected from the group consisting of C^ ^ alkyl, adenyl, guanyl, cytosyl and thymyl esters, and quaternary amraounium sblts - thereof.

15. The method claimed in Claim 13 wherein said salt is potassium peroxydiphosphate.

16. The method claimed in Claim 14 wherein said compound derivative is a C^_i2 ®lkyl ester of peroxydiphosphoric acid. - ■W \J _j_

17. The method claimed In Claim 14 wherein said compound derivative is the adenyl, guanyl, cytosyl, or thymyl ester of peroxydiphosphoric acid.

18. A method of Inhibiting formation of malignant tumor cells in a warm blooded non-human animal in which a composition comprising a non-toxic dosage amount of 0.1-2 gm per kg body weight of a warm blooded non-huinan animal of a non-toxic water-soluble pharmaceutically acceptable compound derivative of peroxydiphosphoric acid dissolved or dispersed in a pharmaceutical carrier which produces a physiological pH of 7.0 to 7.A if administered systemically to a warm blooded non-human animal in a regimen which provides 0.1-2 gm per kg body weight of a warm blooded non-human aninlal per day. J

19. The method claimed in Claim 18 wherein 1 said non-toxic water-soluble pharmaceutically acceptable compound derivative of peroxydiphosphoric acid is a i salt selected from the group consisting of alklai metal, | I alkaline earth metal, zinc and tin salts. j I

20. The method claimed in Claim 18 wherein said j i non-toxic water-soluble pharmaceutically acceptable compound derivative of peroxydiphosphoric acid is selected from the group consisting of ®lkyl, adenyl guanyl, cytosyl and thymylesters and quaternary ammonium salts thereof. *"} ' o ^ t'

21. The method claimed in Claim 19 wherein said salt is potassium peroxydiphosphate.

22. The method claimed in Claim 20 wherein said compound derivative is a C1_12 alkyl, ester of peroxydi- ' phosphoric acid,.

23. The method claimed in Claim 20 wherein said compound derivative is the adenyl, guanyl, cytosyl, or thymyl ester of peroxydiphosphoric acid.

24. The method claimed in Claim 18 wherein said pharmaceutical carrier is a pyrogen-free buffered phosphate saline solution.

25. A method of making tabletted granules having a coating thereon which are not broken down during passage in the stomach and which coating is dissolved by intestinal fluids having a pH of 5.5-10 which comprises blending a non-toxic water-soluble pharmaceutically acceptable compound derivative of peroxydiphosphoric acid with a polvhydroxy sugar solid and wetting the blend with a polyhydroxy sugar compound solution, screening to size, blending a binding agent therewith, compressing to form tabletted granules and coating said tabletted granules by spraying a film of coating solution which is not Inactivated by gastric acids and is dissolved by intestinal fluids having a pH of 5 .5-10.

26. A method of forming a solution of a non-toxic water-soluble pharmaceutically acceptable compound derivative of peroxydiphosphoric acid suitable for stomach administration which comprises sterilizing deionized distilled water to be non-pyrogenie and then adding thereto a phosphate buffer and said compound derivative of peroxydiphosphoric acid and sodium chloride.

27. The composition of claim 1 whenever prepared by a method as claimed in claim 25 or claim 26. WEST-WALKER, McCABE Pen ATTORNEYS FOR THEf^APPLICAMT H.7.. !'A it NT OFFICE -4 JUN 1935 RECEIVED </div>